About elra nata mab bcmm
BCMA-targeted bispecific antibody
Used for
- Treats adults with relapsed or refractory multiple myeloma after at least four prior treatment regimens.
Usual adult dose
Given by a healthcare professional under a specialist’s care: 12 mg on day 1, 32 mg on day 4, then 76 mg weekly through week 24; every two weeks thereafter if responding.
Common side effects
- Cytokine release syndrome
- Infections
- Low blood cell counts
- Nervous system effects, including confusion or dizziness
Important warnings
- Can cause life-threatening cytokine release syndrome; treatment requires monitored step-up dosing.
- Can cause serious neurological problems, including immune effector cell-associated neurotoxicity syndrome.
- Serious infections and low blood counts can occur.
- Treatment is given through a restricted safety program; monitoring is required after doses.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for six months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for six months after the last dose.
Interactions
- May reduce effectiveness of some medicines processed by CYP enzymes, particularly after treatment begins.
- Tell the treatment team about all medicines, vaccines, and supplements; avoid live vaccines during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.